AbbVie Inc. (ABBV) price target and intrinsic value estimate
ABBV's fair price estimate is $136.8.
This valuation is based on a fair P/E of 13.1 and EPS estimates of $10.48, and calculated using the pevaluation method.
ABBV is currently trading at $200.51 (47% overvalued).
The median analyst price target for ABBV is $210.5.
Analyst price targets range from $170.0 to $240.0
Is ABBV overvalued or undervalued?
ABBV is overvalued by 47% using the pevaluation method.
ABBV is undervalued by 5% compared to median analyst price targets.
Current price | $200.5 |
Fair price | $136.8 |
Low analyst price target | $170.0 |
Median analyst price target | $210.5 |
High analyst price target | $240.0 |
Define your own market model and access personalized fair price estimates today!
Health Care
Biotechnology
Market cap:$ 354.17(B)
Enterprise value:$ 411.99(B)
Div. yield:3.09%
P/E:69.86
P/FCF:N/A
P/B:52.22
Historical financials
Showing limited histrical data. Access 10+ years of financials now! Upgrade
Income
RevenueNet IncomeCOGSGross ProfitTotal OpEx.R&DSG&AOperating IncomeInterest ExpenseInterest IncomePre-tax incomeIncome tax
Cash flow
FCFCFONet IncomeD&AStock-based Comp.CFFStock IssuedStock RepurchasedDebt IssuedDebt RepaidDividend PaidCFIAcquisitionsDivestituresCapital Expenditures
Balance sheet
Total AssetsTotal LiabilitiesCurrent assetsCash and EquivalentsShort-term investmentsInventoriesReceivablesNon-current assetsNet PP&EGoodwillCurrent liabilitiesAccounts payableNon-current liabilitiesLong-Term DebtTotal Equity
Shares outstanding
Shares (Basic)Shares (Diluted)
Per share data
EPS (Basic)EPS (Diluted)FCF/ShareDividend/ShareBook value/Share
Ratios
P/EP/FCFP/BP/SEV/EarningsEV/FCFDebt/EquityPayout ratio
Margins
Net Income MarginOperating MarginGross MarginEBITDA MarginFCF Margin
Returns
ROICROAROCEROE
Market Cap.
Market Cap.